Novozymes A/S (NVZMY)
| Previous close | 52.36 |
| Open | 52.48 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 52.45 - 53.33 |
| 52-week range | 45.97 - 71.14 |
| Volume | |
| Avg. volume | 27,108 |
| Market cap | 14.621B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 31.69 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.82 (1.54%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Globe Newswire
Invitation to Novozymes' annual shareholders' meeting 2023
To the shareholders of Novozymes A/S The Board of Directors is pleased to invite you to the company's annual shareholders' meeting on Thursday March 2, 2023 at 4:00 pm CET at Ballerup Super Arena Please read the invitation in PDF Til Novozymes A/S' aktionærer Betyrelsen har hermed fornøjelsen af at invitere dig til selskabets ordinære generalforsamling torsdag den 2. marts 2023 kl. 16.00 i Ballerup Super Arena Læs venligst den fulde invitation i PDF format Attachments Invitation to Novozymes' An
- Globe Newswire
Novozymes delivers historically strong full-year results
Novozymes is delivering strong growth and earnings in a volatile market environment with 9% organic sales growth in 2022. This marks the highest organic sales growth in more than a decade, and Novozymes is confident about the 2023 outlook of 4-7%. COPENHAGEN, Denmark – January 26, 2026. In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before
- Globe Newswire
Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner
Today, Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. COPENHAGEN, Denmark – December 12, 2022. The proposed combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") will create a strong biosolutions group wi
